Search company, investor...

AvidBiotics

avidbiotics.com

Founded Year

2005

Stage

Unattributed | Alive

Total Raised

$6.61M

Last Raised

$850K | 8 yrs ago

About AvidBiotics

AvidBiotics is a developer of non-antibody proteins as targeted therapeutics against bacteria, viral infections and cancers. The scaffolds of AvidBiotics' proteins exhibit functional potency, e.g. killing, exceeding that of antibodies. AvidBiotics has two product platforms. The first is a new class of tailorable, targeted bactericidal agents for use in the treatment or prevention of specific bacterial infections. The second specifically flags virus-infected or cancerous cells for enhanced destruction by the Natural Killer and T-cells of the potent innate immunity system. AvidBiotics focuses on human therapeutic applications of its technologies, both on its own and in partnership with governmental agencies and research institutions, while taking advantage of further near-term collaborative opportunities offered by specific applications of its products and technology platforms in areas such as food safety, biodefense and animal husbandry.

Headquarters Location

100 Kimball Way

South San Francisco, California, 94080,

United States

650-873-1141

Missing: AvidBiotics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AvidBiotics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AvidBiotics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AvidBiotics is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

AvidBiotics Patents

AvidBiotics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/4/2015

9/27/2022

Immune system, Clusters of differentiation, Immunology, Antibodies, Monoclonal antibodies

Grant

Application Date

12/4/2015

Grant Date

9/27/2022

Title

Related Topics

Immune system, Clusters of differentiation, Immunology, Antibodies, Monoclonal antibodies

Status

Grant

Latest AvidBiotics News

Global Human Micobiome Market By Application, By Region, And Segment Forecasts to 2025 | Vedanta, Seres Therapeutics, Second Genome, Rebiotix, ActoGeniX, Enterome BioScience, AvidBiotics, 4D Pharma Research Ltd

Nov 16, 2018

Human Micobiome Market explores effective study on varied sections of Industry like opportunities, size, growth, technology, demand and trend of high leading players. It also provides market key statistics on the status of manufacturers, a valuable source of guidance, direction for companies and individuals interested in the industry. This market research report looks into and analyzes the Global Human Micobiome Market and illustrates a comprehensive evaluation of its evolution and its specifications. Another aspect that was considered is the cost analysis of the main products dominant in the Global Market considering the profit margin of the manufacturers. Major Players in Human Micobiome Market are, Vedanta, Seres Therapeutics, Second Genome, Rebiotix, ActoGeniX, Enterome BioScience, AvidBiotics, 4D Pharma Research Ltd, Enterologics, Metabogen, Metabiomics, Ritter Pharmaceuticals, Osel, Symberix, Miomics, Symbiotix Biotherapies, MicroBiome Therapeutics LLC. This research is categorized differently considering the various aspects of this market. It also evaluates the current situation and the future of the market by using the forecast horizon. The forecast is analyzed based on the volume and revenue of this market. The tools used for analyzing the Global Human Micobiome Market research report include SWOT analysis. This Global Human Micobiome Market research report focuses on the major players in this market throughout the world. This section of the report includes the company profiles, specification and product pictures, production, capacity, contact information, cost and revenue. Likewise, equipment & upstream raw materials and downstream demand analysis is also dealt with. Get Reasonable Discount on this Premium Report:  https://www.reportsweb.com/inquiry&RW00012257188/discount The regional analysis of Global Human Micobiome Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world. Whereas, owing to rising no. of research activities in countries such as China, India, and Japan, Asia Pacific region is also expected to exhibit higher growth rate the forecast period 2015-2025. The Global Human Micobiome Market in terms of investment potential in various segments of the market and illustrate the feasibility of explaining the feasibility of a new project to be successful in the near future. The core segmentation of the global market is based on product types, SMEs and large corporations. The report also collects data for each major player in the market based on current company profiles, gross margins, sales prices, sales revenue, sales volume, photos, product specifications and up-to-date contact information. Table of Content Chapter 1 Global Human Micobiome Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Productions, Revenue (Value) by Region Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions Chapter 6 Global Productions, Revenue (Value), Price Trend by Type Chapter 7 Global Market Analysis by Application Chapter 8 Manufacturing Cost Analysis Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10 Marketing Strategy Analysis, Distributors/Traders Chapter 11 Market Effect Factors Analysis Chapter 12 Global Human Micobiome Market Forecast Contact Us:

AvidBiotics Frequently Asked Questions (FAQ)

  • When was AvidBiotics founded?

    AvidBiotics was founded in 2005.

  • Where is AvidBiotics's headquarters?

    AvidBiotics's headquarters is located at 100 Kimball Way, South San Francisco.

  • What is AvidBiotics's latest funding round?

    AvidBiotics's latest funding round is Unattributed.

  • How much did AvidBiotics raise?

    AvidBiotics raised a total of $6.61M.

  • Who are the investors of AvidBiotics?

    Investors of AvidBiotics include National Institutes of Health.

  • Who are AvidBiotics's competitors?

    Competitors of AvidBiotics include Oceanit, GangaGen, Quantum Leap Innovations, PhaseBio Pharmaceuticals, ForSight VISION4 and 9 more.

Compare AvidBiotics to Competitors

Oceanit Logo
Oceanit

Oceanit creates solutions through engineering consulting in civil, coastal, and environmental engineering; information systems consulting; management consulting, including Design Thinking and scientific research.

R
Receptor Logic

Receptor Logic is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T-Cell Receptors in the immune system. These T-Cell Receptor mimics (TCRms) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines. For more information, visit the company website www.receptorlogic.com.About Emergent Technologies, Inc.Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region.

Bridge to Life Logo
Bridge to Life

Bridge to Life is a biotechnology company that is focused on developing organ preservation solution technologies. Its products include a cold storage solution, a machine perfusion solution, and a sodium chloride solution for slush preparation.

VitrOmics Logo
VitrOmics

VitrOmics (formerly PamGene) develops valuable knowledge and tools in the field of Predictive Genomics. The necessary research are carried out by using in vitro exposure systems based on human cells and applying the latest genomics technologies.

Q
Qbiogene

MP Biomedicals is a supplier of Life Sciences products, diagnostic tools and aims to deliver high quality bulk fine chemicals to the industry.

C
CELBIO SpA

SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.